Nonsuppressible viremia during HIV-1 therapy meets molecular virology.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
    • Publication Information:
      Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
      Original Publication: New Haven [etc.] American Society for Clinical Investigation.
    • Subject Terms:
    • Abstract:
      HIV-1 replication can be suppressed with antiretroviral therapy (ART), but individuals who stop taking ART soon become viremic again. Some people experience extended times of detectable viremia despite optimal adherence to ART. In this issue of the JCI, White, Wu, and coauthors elucidate a source of nonsuppressible viremia (NSV) in treatment-adherent patients - clonally expanded T cells harboring HIV-1 proviruses with small deletions or mutations in the 5'-leader, the UTR that includes the major splice donor site of viral RNA. These mutations altered viral RNA-splicing efficiency and RNA dimerization and packaging, yet still allowed production of detectable levels of noninfectious virus particles. These particles lacked the HIV-1 Env surface protein required for cell entry and failed to form the mature capsid cone required for infectivity. These studies improve our understanding of NSV and the regulation of viral functions in the 5'-leader with implications for rationalized care in individuals with NSV.
    • References:
      J Clin Microbiol. 2014 Nov;52(11):3944-51. (PMID: 25187636)
      J Clin Invest. 2020 Nov 2;130(11):5847-5857. (PMID: 33016926)
      Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1883-8. (PMID: 26858442)
      PLoS Pathog. 2020 Aug 25;16(8):e1008791. (PMID: 32841299)
      RNA. 2020 Jun;26(6):708-714. (PMID: 32205324)
      J Virol. 2010 Aug;84(16):8348-52. (PMID: 20519388)
      Front Biosci. 2003 Jan 01;8:d143-55. (PMID: 12456341)
      AIDS Rev. 2002 Oct-Dec;4(4):195-212. (PMID: 12555694)
      AIDS Res Hum Retroviruses. 2015 Jan;31(1):142-9. (PMID: 25333615)
      Science. 1985 Jul 5;229(4708):74-7. (PMID: 2990041)
      Clin Infect Dis. 2010 Mar 15;50(6):912-9. (PMID: 20156060)
      J Virol. 1995 Aug;69(8):5087-94. (PMID: 7541846)
      J Virol. 1993 Nov;67(11):6365-78. (PMID: 8411338)
      Clin Infect Dis. 2021 Jun 15;72(12):2079-2086. (PMID: 32271361)
      J Virol. 2006 Jul;80(13):6441-57. (PMID: 16775332)
      Nat Rev Microbiol. 2005 Aug;3(8):643-55. (PMID: 16064056)
      Nat Commun. 2021 Jun 17;12(1):3727. (PMID: 34140517)
      Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13378-13383. (PMID: 27834211)
      Virol J. 2016 Sep 21;13(1):157. (PMID: 27655142)
      JAMA. 1999 Nov 3;282(17):1627-32. (PMID: 10553788)
      J Clin Invest. 2023 Mar 15;133(6):. (PMID: 36602866)
      Nature. 2020 Sep;585(7824):261-267. (PMID: 32848246)
      Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9403-8. (PMID: 19470482)
    • Accession Number:
      0 (RNA, Viral)
    • Publication Date:
      Date Created: 20230315 Date Completed: 20230316 Latest Revision: 20230401
    • Publication Date:
      20240628
    • Accession Number:
      PMC10014097
    • Accession Number:
      10.1172/JCI167925
    • Accession Number:
      36919694